Anchiano Therapeutics Appoints Dr. Stephen Hoffman and Robert Connelly to Its Board of Directors

Dr. Stephen Hoffman joins as Chairman

Mr. Connelly is appointed as a Director

 

CAMBRIDGE, Mass., Nov. 12, 2018 – Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointments of Stephen Hoffman, M.D., Ph.D. as Chairman and Robert Connelly as Director to its Board of Directors. Dr. Hoffman has served for over two decades as a Chief Executive Officer, board member, advisor and investment manager in the biopharmaceutical sector. Mr. Connelly has over 18 years of experience as a Chief Executive Officer and in starting, financing, building and leading innovative biotechnology companies.

“We are exceedingly pleased to have both Steve and Bob join our Board of Directors,” said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics. “As Chairman, Steve will be an important mentor to me and strategist to Anchiano, bringing his rich clinical insight, entrepreneurial spirit and far-reaching knowledge of the life sciences industry to the table. Bob, with his extensive history of serving on biotechnology company boards, will be a dynamic and perceptive contributing member to our board. The Anchiano team looks forward to the leadership and insight from two seasoned industry veterans.”

Dr. Hoffman said, “I am excited to be named Anchiano’s Board of Directors Chairman. I am enthusiastic about helping Frank and his team to make an anti-cancer therapy accessible for patients with high unmet needs.

Mr. Connelly stated, “I am delighted to join the ranks of Anchiano’s accomplished board members. Anchiano has laid the groundwork in their clinical development plan for inodiftagene’s being tested in two separate patient populations, potentially providing a new clinical option to patients worldwide.”

About Stephen Hoffman, M.D., Ph.D.
Dr. Hoffman currently serves as Chief Executive Officer of Aerpio Pharmaceuticals, Inc., a public biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. Prior to that, he served as Senior Advisor of PDL BioPharma, Inc., where he focused on product acquisition and structured debt and royalty monetization opportunities. Dr. Hoffman played a major role in portfolio company development at Skyline Ventures, a venture capital firm, where he served as Managing Director, and as a General Partner at TVM Capital. Dr. Hoffman served as President, Chief Executive Officer and a Director of Allos Therapeutics, Inc. where he remained as Chairman until its acquisition by Spectrum Pharmaceuticals, Inc. Dr. Hoffman currently serves on the Board of Directors of Dicerna Pharmaceuticals, Inc., and AcelRx Pharmaceuticals, Inc. Dr. Hoffman completed a fellowship in clinical oncology and a residency and fellowship in dermatology, both at the University of Colorado. He holds a Ph.D. in chemistry from Northwestern University and an M.D. from the University of Colorado School of Medicine.

About Robert Connelly
Mr. Connelly is a seasoned biotech executive having served in senior management roles, including CEO and Board member, for several biotechnology companies. Most recently, Mr. Connelly was a Venture Partner with Flagship Pioneering. During this same time, Mr. Connelly was Chief Executive Officer of Axcella Health, Inc., a clinical-stage therapeutics company developing endogenous modulators of metabolism to treat an array of serious diseases. Mr. Connelly was Chief Executive Officer of Pulmatrix, Inc., a pharmaceutical company developing inhaled drugs for respiratory diseases. Prior to Pulmatrix, he became founding Chief Executive Officer & first employee of Domantis, a UK-based biotech building a novel fully-human antibody fragment platform and pipeline. Mr. Connelly has served on the Board of Directors for WikiCell Designs, Kaliedo and Kintai, and has chaired the Board of Directors for Aero Designs. He received a B.S. in Business Administration from the University of Florida

About Anchiano Therapeutics
Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel. The Company’s most advanced product candidate, inodiftagene vixteplasmid (formerly BC-819), is in development as a treatment for non-muscle-invasive bladder cancer. www.anchiano.com

Forward Looking Statements
This press release contains “forward-looking statements” that are subject to risks and uncertainties. These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to: a lack of history of commercial sales; no anticipated earning operating income over the coming years; a dependence on the success of inodiftagene, the development of which will require significant additional clinical testing before regulatory approval can be sought and commercial sales launched; some scientific or technological difficulties that may be encountered and impede R&D activities; a need to raise substantial additional funds to complete R&D activities; the raising of additional capital may dilute holdings of our existing shareholders, restrict our operations or require us to relinquish rights to our technologies or products; and an ability to obtain and maintain intellectual property protection for product candidates, including pursuant to licensed patents

Company Contact:
Frank Haluska, M.D., Ph.D.
President and Chief Executive Officer
info@anchiano.com

Investor Contact:
Ashley R. Robinson
Managing Director
LifeSci Advisors, LLC
617-535-7742
arr@lifesciadvisors.com